Anti-PAWR antibody produced in rabbit

PRKC apoptosis WT1 regulator protein (PAWR) is a 32-amino acid protein with a leucine zipper domain at its carboxy terminus. The gene encoding it is located on chromosome 12q21. PAWR is commonly referred as PAR4 (Prostate apoptosis response 4 protein).

PRKC apoptosis WT1 regulator protein recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

PRKC apoptosis WT1 regulator protein (PAWR) induces the apoptosis of prostate cancer cells and causes tumor regression. It inhibits the nuclear factor κ-B (NF-κB) activity and also the cell membrane trafficking of Fas (a cell surface death receptor) and Fas ligand (FasL). This leads to the activation of the Fas-Fas-associated death domain-caspase-8 pro-death pathway. The deletion in the gene encoding PAWR leads to pancreatic cancers and male germ cell tumors. PAWR takes part in neuronal degeneration and cholinergic signaling in Alzheimer′s disease. It interacts with CHT1 (a choline transporter) and regulates choline uptake. It functions as a negative regulator of the choline uptake activity by reducing the CHT1 incorporation on the cell surface. WT1 (a transcriptional regulator) has a transcriptional activation domain which can only be activated by specifically interacting with PAWR.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST70988

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.